Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Galmed Pharmaceuticals Ltd. (GLMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/01/2023 6-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. , which includes the Compan...",
"Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results TEL AVIV, Israel, June 1, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023. Recent Developments ● Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis , a rare disease for which there is no approved treatment; ● Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University; ● Formed a strategic partnership with Onkai, Inc., leading an investment round of $6 millio..."
05/17/2022 6-K Quarterly results
11/12/2020 6-K Quarterly results
Docs: "FORM 6-K",
"Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, November 12, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three and nine months ended September 30, 2020. The Company will host a conference call and webcast at 08:30 ET today. Financial Summary – Third Quarter 2020 vs. Third Quarter 2019:"
07/31/2017 6-K Quarterly results
Docs: "FORM 6-K",
"Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update"
05/15/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
03/23/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy